Silexion Therapeutics Corp. announced the successful completion of toxicology studies for SIL204, their siRNA therapy targeting mutated KRAS oncogenes, paving the way for a Phase 2/3 clinical trial in locally advanced pancreatic cancer. SIL204 has shown positive preclinical data inhibiting cancer cell growth and no systemic organ toxicity in two-species studies. The Company plans to submit regulatory applications to Israel and Germany for the trial. Silexion aims to initiate the trial in Q2 2026, demonstrating the potential of SIL204 to treat aggressive cancers by stopping mutated proteins before expression. The unique integrated treatment approach offers hope for improved survival in patients with a reasonable quality of life.

Read more at GlobeNewswire: Silexion Therapeutics Successfully Completes Toxicology